^
    Back
    Association details:
    Biomarker:NPM-ALK fusion
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    LB-100 (PP2A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2022
    Title:

    PP2A Inhibitor LB100 Enhances the Sensitivity of NPM-ALK+ALCL to Crizotinib and Reverses the Resistance of ALCL to Crizotinib

    Published date:
    11/03/2022
    Excerpt:
    The above experiments showed that LB100, as an effective inhibitor of PP2A, can significantly increase the effect of crizotinib against normal NPM-ALK+ ALCL, inhibit the growth of crizotinib-resistant strains, and partially restore the sensitivity of crizotinib, which is expected to be a new therapeutic tool for ALCL.
    DOI:
    10.1182/blood-2022-165718